MedGenesis Therapeutix Inc. MedGenesis Therapeutix Inc.


News ] [ Our People ]

Our People

[Management Team ] [ Board of Directors ]

Board of Directors

ErichErich Mohr, Ph.D., ICD.D.
Chairman & Chief Executive Officer
Founder of MedGenesis Therapeutix Inc.

Dr. Mohr is the Chairman and CEO of MedGenesis Therapeutix Inc. which he founded in 2006. Dr. Mohr, a Professor of Medicine and Psychology at the University of Ottawa until 1997 has over 30 years of experience in experimental therapeutics of CNS disorders. He is credited with over 150 publications, book chapters and abstracts and has edited the Handbook of Clinical Trials: The neurobehavioral approach. Dr. Mohr has chaired and/or served on several regulatory advisory panels for the approval of new products for the treatment of neurodegenerative disease and is the former Chairman and Chief Executive Officer of CroMedica Global Inc. (which merged with PRA International in 2002 to form one of the world's leading contract research organizations) and is the current or past Chairman of several biotechnology companies. His most recent executive position was with PRA International as Chief Scientific Officer. He also served until recently as Chair of the Board of Governors of the University of Victoria. Over the course of his career, Dr. Mohr has overseen and/or participated in more than a dozen clinical development programs resulting in a number of approved drugs.


PatPatrick (Pat) K. Donnelly
Operating Partner and Board Director, ProPharma Group and Advarra
Board Director, Phase 5 LLC and Rediscovery Life Sciences

Mr. Donnelly, who has more than 35 years of experience, was most recently Chairman and Chief Executive Officer of Aptiv Solutions, a global pharmaceutical development services business he founded which was sold to ICON (NASDAQ:ICLR) in May 2014. Prior to this, Pat served as President, Chief Executive Officer, and was one of the founders of PRA International (now PRA Health Sciences, NASDAQ:PRAH). He was instrumental in building PRA over a period of twelve years from a small regional contract research organization to a global leader in the industry. Mr. Donnelly received his MBA. from Pennsylvania State University in 1984 and received his BS from the University of Missouri in 1980. Pat currently serves as an Operating Partner and as a board director for Linden portfolio companies, ProPharma Group and Advarra. Pat is also a board director at Phase 5 LLC, and Rediscovery Life Sciences.


ChrisH. Christian Fibiger, Ph.D.
Independent Board Member
Associate Dean, Research, University of British Columbia

H. Christian Fibiger received his BSc in Chemistry and Psychology from the University of Victoria and his PhD in Psychopharmacology from Princeton University. He is currently Associate Dean, Research, in the Faculty of Medicine at the University of British Columbia. Dr. Fibiger was formerly the Chief Scientific Officer and Senior Vice President at Biovail Laboratories International (2008 - 2010). From 2003 until 2007, he was Vice President and Global Head of Neuroscience at Amgen. In this position he was responsible for Amgen's worldwide Neuroscience discovery efforts ranging from early exploratory research through clinical candidate selection. Prior to joining Amgen in 2003, Dr. Fibiger served as Vice President of Neuroscience Discovery Research and Clinical Investigation, and Lilly Research Laboratories in Europe at Eli Lilly and Company. Dr. Fibiger previously served as Professor and Head of the Division of Neurological Sciences and Chair of the University Graduate Program in Neuroscience at the University of British Columbia. Professor Fibiger has made numerous contributions to neuroscience research and, during his academic career, was among the world's 100 most cited scientists in neuroscience. He has received many honors for his research contributions, including the Clark Institute Prize in Psychiatry, the Heinz Lehmann Award of the Canadian College of Neuropsychopharmacology, the Killam Research Prize, the Gold Medal in Health Sciences from the Science Council of British Columbia, and the Tanenbaum Distinguished Scientist Award in Schizophrenia Research. He is a Fellow of the American College of Neuropsychopharmacology. Professor Fibiger has served on the editorial boards of major neuroscience journals and was co-editor of Neuropsychopharmacology, the official publication of the American College of Neuropsychopharmacology. He currently serves on the Board of several for profit and nonprofit organizations.


KenKen Newport
Former President, CroMedica Global Inc.

Ken Newport is an entrepreneur and life sciences business executive. As a graduate of the University of Waterloo and a Chartered Accountant, Mr. Newport had early success in the financial services industry and served as a partner in a Chartered Accounting firm. His focus changed to life sciences in the mid-nineties with the formation of CroMedica Global Inc., a contract research organization. As co-founder and President he witnessed CroMedica's growth to 600 employees within six years. By the time that CroMedica merged with PRA International Inc. in 2002 CroMedica had annual revenues of over $40 million with 13 offices in 9 countries. The combined company became one of the 5 largest contract research organizations in the world with 2,600 employees. Mr. Newport served as a Senior Vice President and Executive Committee member until 2005. Mr. Newport was also a founding member of Global Biomedical Capital Corporation, Zelos Therapeutics Inc., Prime Trials Inc. and other life science organizations. He is now a corporate director and has earned the ICD.D designation. He serves or has served on several corporate and not for profit Boards including his role as Chairman of BioCanRx.


GregGreg Johnson
Principal Consultant, Cagley Johnson Consulting Inc.

Greg Johnson has more than 25 years of experience in Biotech and Clinical Research, with recognized expertise in strategic planning, project management and operations management, as well as in electronic data capture and the implementation and use of computerized systems in a clinical research setting. Mr. Johnson is a principal with Cagley Johnson Consulting Inc. Prior to founding his consulting company, he was Chief Operating Officer then President and Chief Financial Officer for MedGenesis Therapeutix (2007-2017). Mr. Johnson previously held a number of senior roles at PRA International (1992-2007; now PRA Health Sciences) in four different countries. Mr. Johnson has an M.Sc. in Clinical Research from Liverpool John Moores University, professional certification (PMP) through the Project Management Institute and is a Fellow of the Institute of Clinical Research (FICR).




MedGenesis Therapeutix Inc.